Nintedanib for Improving Reproductive Outcomes in Adenomyosis

Официальное название

A Single-center, Randomized, Prospective, Controlled Clinical Study on the Efficacy of Nintedanib in Improving Reproductive Outcomes in Women With Adenomyosis

Обзор

This study aims to evaluate the effectiveness and safety of nintedanib, an antifibrotic drug, in improving live birth rates for infertile women with adenomyosis who have frozen embryos. Based on promising animal data showing reduced uterine fibrosis, participants will be randomized to receive either standard progesterone therapy plus nintedanib or progesterone therapy alone for three months before undergoing a frozen embryo transfer cycle.

Вмешательства

• Препарат Nintedanib
  Participants will be randomly assigned to one of two groups: the Experimental Group will receive oral nintedanib (100 mg twice daily) plus progesterone therapy for three months; the Control Group will receive progesterone therapy only.
• Препарат Progesterone
  For control group

Первичные конечные точки

• live birth rate [Срок оценки: Up to approximately 9-12 months after embryo transfer (considering gestation)]

Критерии участия

Критерии включения

Aged 20-38, diagnosed with primary or secondary infertility; with at least one vitrified high-quality blastocyst (grading ≥4BB).

Diagnosed with adenomyosis within the last 3 months by MRI or transvaginal ultrasound, meeting the criteria of the Chinese Expert Consensus on Diagnosis and Treatment of Adenomyosis.

Body Mass Index (BMI) between 18-27 kg/m².

Regular menstrual cycles, no amenorrhea or severe dysfunctional uterine bleeding.

Normal ovarian reserve (AMH > 1 ng/mL or AFC ≥ 5 per ovary), not currently receiving ovarian suppression therapy.

Signed informed consent, able to understand and voluntarily participate, and willing not to participate in other clinical trials during the study period.

Критерии исключения

Uterine or adnexal abnormalities (e.g., intrauterine adhesions, unicornuate/bicornuate/arcuate uterus, unremoved hydrosalpinx, endometrial polyp, submucosal myoma, or intramural myoma distorting the endometrial cavity).

History of GnRH agonist injection within 3 months prior to embryo transfer.

Unexplained abnormal vaginal bleeding.

Known active pelvic inflammatory disease.

Known genital malformation unsuitable for pregnancy.

Abnormal cervical cytology (TCT) results within 1 year before screening.

Severe impairment of liver or kidney function, heart disease, or hypertension.

Known history of thrombophlebitis or thromboembolic disease.

Any known clinically significant systemic disease (e.g., diabetes, tuberculosis).

Known history of recurrent miscarriage.

Chromosomal karyotype abnormality in either partner.

Either partner has a genetic disease deemed unsuitable for childbearing per the "Maternal and Infant Health Care Law".

Either partner has been exposed to teratogenic levels of radiation, toxins, or drugs.

Any condition/combined surgery/medication/other clinically significant abnormal lab finding judged by the investigator to potentially affect trial results.

Known refusal or inability to comply with the protocol requirements for any reason.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT07162961 · New IVF

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗